140 related articles for article (PubMed ID: 28450788)
1. Effects of
Charoenchokthavee W; Areepium N; Panomvana D; Sriuranpong V
Breast Cancer (Dove Med Press); 2017; 9():249-256. PubMed ID: 28450788
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.
Charoenchokthavee W; Panomvana D; Sriuranpong V; Areepium N
Breast Cancer (Dove Med Press); 2016; 8():149-55. PubMed ID: 27540311
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
[TBL] [Abstract][Full Text] [Related]
4. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.
Saghafi F; Salehifar E; Ebrahimi P; Shiran MR; Zaboli E; Sohrevardi SM; Jamialahmadi T; Sahebnasagh A; Sahebkar A
J Pharm Biomed Anal; 2024 Jan; 238():115839. PubMed ID: 37976989
[TBL] [Abstract][Full Text] [Related]
6. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
7. Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.
Schroth W; Winter S; Mürdter T; Schaeffeler E; Eccles D; Eccles B; Chowbay B; Khor CC; Tfayli A; Zgheib NK; Eichelbaum M; Schwab M; Brauch H
Front Pharmacol; 2017; 8():582. PubMed ID: 28955222
[No Abstract] [Full Text] [Related]
8. Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.
Lee CI; Low SK; Maldonado R; Fox P; Balakrishnar B; Coulter S; de Bruijn P; Koolen SLW; Gao B; Lynch J; Zdenkowski N; Hui R; Liddle C; Mathijssen RHJ; Wilcken N; Wong M; Gurney H
Breast; 2020 Dec; 54():229-234. PubMed ID: 33161337
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients.
Areepium N; Panomvana D; Rungwanonchai P; Sathaporn S; Voravud N
Breast Cancer (Dove Med Press); 2013; 5():73-8. PubMed ID: 24648760
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trial:
Khalaj Z; Baratieh Z; Nikpour P; Schwab M; Schaeffeler E; Mokarian F; Khanahmad H; Salehi R; Mürdter TE; Salehi M
Front Pharmacol; 2019; 10():530. PubMed ID: 31178724
[No Abstract] [Full Text] [Related]
11. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
12. Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Dohollou N; Bernard-Marty C; Laharie-Mineur H; Filleron T; Roché H; Chatelut E; Thomas F; White-Koning M
Clin Pharmacol Ther; 2021 May; 109(5):1244-1255. PubMed ID: 33047329
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen.
Kanji CR; Nyabadza G; Nhachi C; Masimirembwa C
J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836506
[TBL] [Abstract][Full Text] [Related]
14.
Ahmed JH; Makonnen E; Fotoohi A; Aseffa A; Howe R; Aklillu E
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547390
[TBL] [Abstract][Full Text] [Related]
15. Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer.
Chiwambutsa SM; Ayeni O; Kapungu N; Kanji C; Thelingwani R; Chen WC; Mokone DH; O'Neil DS; Neugut AI; Jacobson JS; Ruff P; Cubasch H; Joffe M; Masimirembwa C
Clin Pharmacol Ther; 2023 Jul; 114(1):127-136. PubMed ID: 37042388
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
17. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
[TBL] [Abstract][Full Text] [Related]
18. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
19. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
[TBL] [Abstract][Full Text] [Related]
20. Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.
Dickschen K; Eissing T; Mürdter T; Schwab M; Willmann S; Hempel G
Springerplus; 2014; 3():285. PubMed ID: 24936398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
